Drug profile · INN
omidenepag isopropyl
OMLONTI
omidenepag isopropyl (OMLONTI) is a prostanoid ep2 receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — omidenepag isopropyl
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
omidenepag isopropyl (OMLONTI) is a prostanoid ep2 receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid EP2 receptor agonist
Primary target: Prostaglandin E2 receptor EP2 subtype
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is omidenepag isopropyl?
omidenepag isopropyl (OMLONTI) is a prostanoid ep2 receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for omidenepag isopropyl?
OMLONTI is a marketed brand name for omidenepag isopropyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omidenepag isopropyl?
omidenepag isopropyl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.